Single-nucleotide polymorphism (SNP) array analysis was performed using the 10K GeneChip array on a series of 26 paired follicular lymphoma (FL) and transformed-FL (t-FL) biopsies and the lymphoma cell lines SCI-1, DoHH2 and RL2261. Regions of acquired homozygosity were detected in 43/52 (83%) primary specimens with a mean of 1.7 and 3.0 aberrations in the FL and t-FL, respectively. A notable feature was the occurrence of recurring sites of acquired uniparental disomy (aUDP) on 6p, 9p, 12q and 17p in cell lines and primary samples. Homozygosity of 9p and 17p arose predominantly in t-FL and in three cases rendered the cell homozygous for a preexisting mutation of either CDKN2A or TP53. These data suggest that mutation precedes mitotic recombination, which leads to the removal of the remaining wild-type allele. In all, 18 cases exhibited abnormalities in both FL and t-FL samples. In 10 cases blocks of homozygosity were detected in FL that were absent in the subsequent t-FL sample. These differences support the notion that FL and t-FL may arise in a proportion of patients by divergence from a common malignant ancestor cell rather than by clonal evolution from an antecedent FL.
Introduction
Follicular lymphoma (FL) is the second most common B-cell malignancy representing one-quarter of non-Hodgkin's lymphomas (NHL). Although the disease has a relatively long median survival of 8-10 years 1,2 and patients have initially a high rate of response, the illness follows a fluctuating course of progression punctuated by remissions of variable duration. For as many as half of patients, transformation to a more aggressive lymphoma may occur, usually diffuse large B-cell lymphoma transformed-FL (t-FL), and this event is often associated with a particularly poor response to treatment. [3] [4] [5] [6] Although up to 85% of FL cases are characterized by the t(14;18)(q32;q21) translocation, clinical heterogeneity is reflected in a complex accumulation of secondary genetic events within these tumours, [7] [8] [9] many of which are present in only a subset of specimens. 9 The mechanism of transformation and the relationship between the two disease stages remain obscure. Comparative genomic hybridization (CGH) analysis of sequential FL and t-FL biopsy samples has been used to determine the critical copy number changes in these tumours. [10] [11] [12] [13] More recently, arraybased high-density genotype analysis has become available. The application of this approach to other malignancies has not only revealed copy number changes but has also uncovered the presence of large regions of homozygosity in the absence of copy number change. [14] [15] [16] [17] [18] Such regions, which have been termed acquired uniparental disomy (aUPD) or isodisomy, appear to be due to mitotic recombination between the two chromosomal homologues 19 and are undetectable by CGH array technology. These events can result in the selection of daughter cells made homozygous for a pre-existing mutation. [20] [21] [22] [23] [24] We have used single nucleotide polymorphism (SNP) array technology to investigate regions of loss of heterozygosity in the absence of copy number change in order to establish the contribution of these abnormalities to the evolution of FL and t-FL.
Materials and methods

Tissue samples
Fifty-two tumour specimens derived from 26 patients with FL that subsequently transformed to diffuse large B-cell lymphoma, referred to as t-FL, were identified from the tissue archive at St Bartholomew's Hospital, London. These patients formed part of a tumour panel of 29 patients reported previously and the patient numbering has been maintained. 25 Patients 3, 14 and 29 were excluded from analysis as DNA was limited. In the remaining 26 patients (median 45 years ), transformation occurred a median of 3.8 years (range 1-14.6 to years) after presentation, with patients having received a median of 3 (0-13) therapies before transformation. Median follow-up from diagnosis for all patients at the time of analysis was 16 years (range 2-21 years). The median age at transformation was 52 (range 27-73) years. Presentation lymph nodes were analysed in 10/26 patients ( Patients 6, 7, 9, 12, 17, 19, [20] [21] [22] [23] [24] [25] . The t(14;18)(q32;q21) cell lines DoHH2, RL2261 and SCI-1 were also included for analysis. Local Research Ethics Committee approval was obtained before initiation of the study.
10K 2.0 GeneChip assay
Genomic DNA was extracted from snap-frozen lymph nodes by conventional methods. DNA probes were prepared using the GeneChip mapping assay protocol (Affymetrix Inc., Santa Clara, CA, USA) with the modification that PCR products were purified using the Ultrafree-MC filtration column (Millipore, Billerica, MA, USA). Signal intensity data were analysed by the GeneChip DNA analysis software, which uses a model algorithm to generate SNP calls. Regions of alteration were defined by the presence of 496% homozygosity in at least 50 contiguous SNPs using a custom designed software, genome oriented laboratory file (GOLF). Information on GOLF is available on request from Professor Bryan D Young, (email: bryan.young@cancer.org.uk) and software package and guidelines for use of the GOLF Programme are accessible at http://www.cancer.qmul.ac.uk/ staff/young.html. The copy number ratio was calculated against a combination profile of six germline DNA samples (Supplementary Information).
Mutation analysis
Aliquots of DNA were diluted to a final concentration of 50-100 mg/ml. Primers and precise amplification conditions were derived either from previously published studies or cDNA/ genomic comparison, and are available on request. Selective screening of patient DNA was performed as determined by its corresponding homozygosity profile. Mutation analysis was carried out by PCR-direct sequence analysis of selected regions of protein tyrosine phosphatase, non-receptor type 11 (PTPN11) (exons 3 and 13); 26 histone H4 (HIST1H4D), Splicing factor, arginine/serine-rich 3 (SFRS3), cyclin-dependent kinase inhibitor 1A (CDKN1A/p21 WAF1/CIP1 ), 27 cyclin D3 (CCND3) and cyclin-dependent kinase inhibitor 2A (CDKN2A) were all screened in their entirety. Tumour protein 53 (TP53) screening of this series has been published previously. 25 PCR products were sequenced directly by use of an ABI 377 DNA sequencer (PE Applied Biosystems, Foster City, CA, USA). Unincorporated primers were removed by ultrafiltration and sequencing data analysed using DNAStar (DNAStar Inc., Madison, WI, USA).
Results
Pattern of abnormalities in paired FL and t-FL biopsies
SNP genotype arrays were used to analyse homozygosity patterns in sequential samples obtained from 26 patients who had at least one episode of FL and t-FL. For most of these paired samples, germline DNA was unavailable. It was therefore necessary to establish a criterion for the detection of abnormal runs of homozygosity. The presence of 496% homozygosity in at least 50 contiguous SNPs was found to detect no abnormalities in DNA of 23 remission bone marrows (data not shown) and was therefore adopted. As the mean physical distance between individual SNPs on the 10K chip system is 258 kb these parameters will bias detection to long runs of homozygosity. Using this criterion, blocks of homozygosity representing acquired regions of UPD (black), deletion (green) and amplification (red) were detected in 43/52 (83%) lymph node biopsies with an average 1.7 and 3.0 aberrations detected in FL and t-FL, respectively ( Figure 1) .
Overall, the number of FLs exhibiting abnormalities (20/26: 77%) was lower than that observed for t-FL (23/26: 88%) with 18 patients having detectable abnormalities in both episodes of disease. The pattern of aberration detected in these patients was consistent with two distinct mechanisms of transformation. t-FL appeared to arise by a process of direct evolution in eight patients where the aberrations detected in FL were maintained at transformation. Figure 2a shows a genomic profile obtained from patient 9 who exhibited a block of homozygosity on 12q in both FL and t-FL samples with the acquisition of several additional abnormalities within the t-FL sample. The other 10 patients have a more complex pattern with the detection of Figure 1 A summary of the regions of homozygosity (regions with 496% homozygous calls in a minimum region of 50 contiguous SNPs) in paired FL-tFL biopsies and three cell lines (DoHH2, RL2261, SCI-1) for each chromosome in the samples analysed using the 10 K 2.0 SNP array (see also Supplementary data). Black: represents regions of homozygosity without significant chromosome copy number changes (signal intensity ratio compared between 0.75 and 1.25); green, regions of homozygosity with relative chromosome copy number loss (signal intensity ratio, o0.75); red, regions of homozygosity with relative copy number gains (signal intensity ratio41.25). Presentation FL samples were analysed in 10/abnormalities within the FL that were absent at transformation. Figure 2b shows the genomic profile obtained for case 21 that harbours aberration on chromosomes 1, 2, 3, 4 and 13 within the FL sample that were absent at transformation. The detection of regions of homozygosity on 2p and 6p common to both FL and t-FL in this patient suggests that these lymphomas evolved separately from an ancestor B cell. Eight pairs had at least one biopsy in which no abnormalities were detectable (Figure 1 ). These cases were not included for direct comparison as we are unable to discriminate between samples having no abnormality and those where the existence of contaminating normal DNA within the sample may have prevented the detection of changes within these tumours.
SNP genotype analysis was also performed on remission bone marrow DNA available in six cases (7, 8, 16, 18, 20 and 21) . In all but one case the observed homozygosities were absent from the remission sample demonstrating that these were somatically acquired. A single 11 Mb region of homozygosity on 11p seen in both FL and t-FL of patient 8 was also present in the remission bone marrow indicating that this was a feature of the patient's germline DNA. The existence of large regions of germline homozygosity are rare and are more commonly associated with particular recessive disorders. 28 
Recurrent sites of homozygosity
Seventy-eight of the 120 homozygous events (65%) detected represented regions of aUPD. Such abnormalities were found in 23/26 (88%) tumour pairs involving 16 different chromosomes (range 1-6). Regions of recurring aUPD (n43) were localized to chromosomes 6, 9, 12 and 17. The size of these regions was variable, included whole chromosomes (6) or chromosomal arms (6p, 9p, 12q, 17p) and usually ran from a point on the chromosome to the telomere.
aUPD6p-tel was detected in four patients (12, 17, 21 and 26) , where the block of homozygosity was present in both FL and the corresponding t-FL biopsy. aUPD arose in two further cases (5 and 15) from an apparent loss and duplication of the whole chromosome 6 (Figure 3a) . Patient 2 showed a region of There was an increase in the number of no calls for the SNPs residing on either side of this region. This no call profile suggests that normal contaminating cells may be masking the detection of aUPD6p-tel in this sample. Overall, the boundaries of mitotic recombination on 6p all locate within an approximate 10 Mb (34-44 Mbs) region of p21 (Figure 3b) . Homozygosity of 9p occurred in six patients and included three cases each with a deletion (8, 9 and 27) or aUPD (10, 18 and 28) of 9p. These alterations were present in three of the FL specimens and in all six corresponding t-FL. Patient 8 had a deletion in the FL biopsy and a region of aUPD in the t-FL sample. Regions of aUPD12q were detected in five patients (1, 5, 9, 13 and 19) with a further two patients with amplification of 12q (15, 22) . aUPD12q was detected in FL and t-FL biopsies with the site of mitotic recombination arising within a 13 Mb region of 12cen-q13 (33-46 Mbs) in three cases (9, 13 and 19) (Figure 1) . Finally, all five cases identified with homozygosity of 17p (4, 8, 9, 10 and 22) had arisen in cases of t-FL.
aUPD of lymphoma cell lines
The t(14;18)-bearing cell lines SCI-1, DoHH2 and RL2261 were subjected to similar genotype analysis. It was notable that these cell lines also contained regions of aUPD similar to those seen in primary tumour material: SCI-1 (6p, 12q and 17p); DoHH2 (9p and 12q) and RL2261 (12q and 17p) (Figure 1) . Additionally, the investigation of copy number data identified a small homozygous deletion on 9p in DoHH2 (Figure 4 ).
Mutation studies
Mutation analysis was performed for genes previously found to be deregulated in haematological malignancies and locating to sites of homozygosity on 6p (HISTY1H4D, SFRS3, CDKN1A and CCND3), 9p (CDKN2A), 12q (PTPN11) and 17p (TP53). No mutation was detected in the coding region of genes localizing to 6p or 12q. Patient 27 had a heterozygous missense mutation in CDKN2A (385 T4G: Y129D) (data not shown). Homozygosity of 17p was observed in five patients and was restricted aUPD in follicular lymphoma J Fitzgibbon et al to t-FL. TP53 mutation status of these biopsies were included as part of a previous study. 25 Two of these patients, 4 (13344 T4C: I195T) and 22 (13129_13130 ins C frameshift) showed homozygous mutation in their t-FL biopsy. Case 9 was heterozygous for a TP53 mutation (14057 G4T: G244C) that was also detected in the corresponding FL biopsy sample. There were no mutations observed in samples obtained from patients 8 or 10.
Discussion
High-density array-based SNP analysis provides an efficient means to determine sites of aUPD within the cancer genome. The acquisition of aUPD is nonrandom, varies within and between cancers, 15, 29, 30 and in leukemia is frequently associated with homozygous gene mutation. [20] [21] [22] [23] [24] In FL the mutational status of genes is less established and the secondary events more complex. We therefore sought to determine whether aUPD also arose in these tumours and how these events could contribute to the clinical evolution of the disease.
Regions of aUPD were detected in the majority of samples and located to 16 different chromosomes. This figure may well be an under-representation of the actual frequency of aUPD, as the criterion set to distinguish between aUPD and the normal occurrence of homozygosity within the genome in this study is biased towards long regions of homozygosity that encompass a minimum of 50 contiguous SNPs. As the mean separation between adjacent SNPs on the 10K system is approximately 258 kb, sizeable regions of aUPD are very likely to go undetected. This inherent bias for abnormalities spanning large distances may explain the high frequency of aUPD events involving whole chromosome arms, the absence of events on the shorter chromosomes and their preponderance over changes in DNA copy number that typically locate to discrete chromosomal regions.
The occurrence of normal cells within the tumour is a recognized and prognostic marker in FL 31 with the amount of infiltrate varying between biopsy with a mean of approximately 30% (Randy Gascoyne, personal communication). This is likely to lead to a masking and an under reporting of acquired homozygosity events. In a series of diluting experiments using both the Illumina and Affymetrix platforms, where tumour and its corresponding normal cells were mixed at differing proportions, approximately 70% tumour content was defined as a lower limit for the detection of aUPD. [32] [33] [34] The presence of nontumour cells therefore is the most likely explanation for the absence of acquired homozygosities in 23% of the biopsies tested in this study and/or the occurrence of no calls within these tumours as seen on 6p in patient 2. The possibility however that these biopsies do not harbour regions of homozygosity can not be excluded completely since 10% of t(14;18) þ ve FL do not harbour secondary cytogenetic abnormalities. 9 Normal cell contamination will have an even greater effect on mutation analysis particular when attempting to discriminate between heterozygous and homozygous gene mutation. In contrast with aUPD, where 50% of DNA from the normal contaminating cells will contribute to the aUPD profile, all DNA arising from the normal cell pool will contribute wild-type sequence. This provides an explanation for the presence of heterozygous mutation for patients 9 and 27 in TP53 and CDKN2A, respectively where homozygous mutations would be expected based on their aUPD profiles. We cannot however rule out the possibility that mutation in CDKN2A or TP53 arise following mitotic recombination and are not therefore the basis of daughter selection and the acquisition of aUPD.
To search for underlying genetic lesions made homozygous in FL we analysed four regions of recurrent aUPD on chromosomes 6, 9, 12 and 17. These chromosomal regions have all been implicated previously in the pathogenesis of FL. 9 As our study in leukemia indicated that mitotic recombination and the resultant UPD has a role in rendering a leukemic cell homozygous for a pre-existing sequence mutation we have restricted our initial studies in lymphoma to the search for alterations in the coding region of selective genes. Mutation of CDKN2A (9p) and TP53 (17p) are established secondary events in transformation 7, 25, 35, 36 and homozygous mutation of these genes was identified in three cases (DoHH2: CDKN2A; patients 4 and 22: TP53). This confirmed our previous observations in AML that mutation precedes mitotic recombination which represent a second hit resulting in the removal of the remaining wild-type allele. 24 The absence of mutation in other samples with aUPD 9p or 17p may reflect the existence of either additional mutational targets on these chromosomes or alternative mutational mechanisms, for example, methylation of CDKN2A. 35 The finding of a single mutation (patient 27) within the patient panel is in agreement with previous studies showing only rare mutation of CDKN2A in FL. 36 The occurrence of 6p and 12q abnormalities in both FL (diagnostic and relapse samples) and t-FL samples suggests that these aberrations may represent early events in the development of the disease. ) subject to deregulation in haematological malignancy. As the number of independent samples harbouring aUPD6p is limited and in the absence of matching germline material to map with confidence the precise recombination boundaries, genes mapping within or distal of this mitotic recombination cluster region were included for mutation analysis. No mutations have been identified in the genes tested ( Figure 3b) ; it seems likely that the selective basis of aUPD in lymphoma will prove more difficult to resolve than in AML where the gene targets are better established. We are also unable to rule out the possibility that epigenetic changes or shifts in tumour allelotype could be responsible for daughter selection following mitotic recombination. We expect that the accumulation of additional cell line (for example, see www.sanger.ac.uk/ genetics/CGP/CopyNumberMapping/) and biopsy material with aUPD6p, and the use of higher density arrays will assist in defining minimal boundaries of aUPD and narrow attention to a smaller number of genes. This is also the case for aUPD12q where the region of aUPD includes a large portion of the long arm of the chromosome. Silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) has been proposed as the Figure 4 Chromosome 9 copy number ratio (log 2 ratio) at each SNP locus for the cell line DoHH2. SNPs are plotted (dots) as per chromosomal location from p arm (left) to q arm (right). DoHH2 exhibits both aUPD9p and a homozygous deletion of SNPs spanning the CDKN2A locus (located between the vertical lines).
aUPD in follicular lymphoma J Fitzgibbon et al candidate gene in this region 43 as it resides within a recurrent breakpoint region on 12q24 region in transformed NHL. Since SMRT is deleted in only one copy of 12q in the DoHH2 cell line it seems unlikely to act as the selective basis of aUPD on this chromosome.
Eighteen of the 26 patients exhibited abnormalities in both FL and t-FL samples. SNP genotype analysis detected abnormalities in 10 of these FL tumours, which were absent in the corresponding transformed episodes of the disease. It is possible therefore that FL and t-FL may arise independently from a B-cell precursor 44 and not through the emergence of a more aggressive, subclone of cells from within the FL pool. This hypothesis, based initially on the clonal relationship of Ig V H DJ H sequence variability in a case of FL and t-FL, 44 represents an important new concept to emerge in this field and could have significant clinical and therapeutic relevance. On the basis of the natural history of FL transformation one can speculate that the events giving rise to FL from this proposed B-cell precursor may be more easily acquired than for the onset of t-FL. There is however very little data to ascertain the frequency of de novo DLBCL recurring with FL for a direct comparison to be made.
The use of SNP genotype analysis provides a further means of visualizing the genomic changes responsible for cancer development and sites of UPD that go undetected by previous methods. Although the clinical heterogeneity of FL is still reflected in a complex accumulation of genetic events the current study has identified mitotic recombination as a key event in the origin and evolution of this disease.
